Prognostic value of plasma biomarkers for informing clinical trial design in mild-to-moderate Alzheimer’s disease

Table 3 Linear regression models predicting 48-week QUARC change on bilateral lateral ventricles and mid-temporal volumes by baseline value of each plasma biomarker after adjusting for age, sex, years of education, APOE ε4 status, treatment arm, and baseline ADAS-Cog11 score

	Std. coefficient	SE	t value	P value	95% CI Lower.bound	95% CI Upper.bound	Bonferroni adjusted P value
Bilateral Lateral Ventricles volume 48-week QUARC change
GFAP	0.64	0.44	1.46	0.146	−0.23	1.51	0.728
NfL^**	1.30	0.44	2.96	0.004	0.43	2.17	0.018
P-tau181^*	0.92	0.42	2.20	0.030	0.09	1.75	0.148
T-tau	0.30	0.41	0.74	0.463	−0.50	1.10	1.000
Aβ42/40	0.01	0.43	0.02	0.983	−0.84	0.85	1.000
Mid-temporal volume 48-week QUARC change
GFAP^**	−0.49	0.13	−3.78	0.000	−0.74	−0.23	0.001
NfL^**	−0.47	0.14	−3.47	0.001	−0.74	−0.20	0.003
P-tau181^**	−0.38	0.13	−3.05	0.003	−0.63	−0.13	0.013
T-tau	0.03	0.12	0.21	0.835	−0.22	0.27	1.000
Aβ42/40	0.10	0.12	0.79	0.432	−0.15	0.34	1.000

^*Indicates the unadjusted p-value was significant (p < 0.05)
^**indicates the family-wise Bonferroni adjusted p-value was significant (p < 0.05)

ISSN: 1758-9193